WALTHAM, Mass.--(BUSINESS WIRE)--May 9, 2006--Interleukin Genetics, Inc. (AMEX: ILI - News) today reported financial results for the quarter ended March 31, 2006. The company generated revenue of $232,000 and a net loss of $1.6 million or $0.07 per basic and diluted common share for the quarter. Interleukin Genetics' reported revenues resulted almost entirely from the processing of genetic tests for cardiovascular health and general nutrition.
